1. Enabling Rapid and Accurate Cancer Diagnosis
SynderBio
4/29/2019
SynderBio
Enabling Rapid and Accurate Cancer Diagnosis
Partnering for Growth
Biotech Innovation Showcase
March 20, 2018
© 2018 SynderBio, Inc.

2. SynderBio Corridor Angels Presentation
4/29/2019
SynderBio: Lab Automation & Cancer Dx Company with Patented Core Technology
Targeted
Cell Depletion
Rapid Results
Biopsy Processing in Lab & Clinic
R&D Labs
Urology
Product-Market Fit in Several Large Markets
Oncology
Contact:

3. SynderBio
4/29/2019
Millions of Bladder Cancer Survivors: Regular Surveillance, Invasive Procedures
$1B spent annually in US on bladder cancer surveillance. Most costly cancer to manage per case.
Patient Surveillance
$1B
2.7M people worldwide are living with bladder cancer.
79,000 new cases in US in 2017.
Bladder Cancer Patients
2.7M
4x per year, bladder cancer survivors undergo cystoscopy, an invasive and costly procedure.
4x/year
Invasive Procedures
No non-invasive test to diagnose recurrent bladder cancer is considered effective enough to replace invasive cystoscopy.
Unmet Need
American Cancer Society, 2017
Contact:
Pharmacoeconomics, (11): p

4. SynderBio
4/29/2019
Current surveillance is costly and invasive. Non-invasive tests are not accurate for surveillance. VS
Cystoscopy: The current standard of care is quarterly cystoscopy, an invasive procedure performed by urologist.
Urine-Based Cytology: Non-invasive test use voided urine to screen for cancer. Currently not considered sensitive enough for recurrent bladder cancer.
Contact:

5. Enhanced Non-Invasive, Urine-Based Cytology
SynderBio
4/29/2019
Enhanced Non-Invasive, Urine-Based Cytology
Used for decades to detect advanced bladder cancer
Performed using voided urine from patient
SynderBio Solution : Cytology is enhanced by the removal of benign cells. Only cancer cells remain, leading to accurate diagnosis.
Now: Pathologists cannot determine if some suspicious cells in recurrent cancer are malignant or benign.
Benign Sample
Malignant Sample
Benign Sample
Malignant Sample
Standard Cytology
After Processing with SynderBio Instrument
Contact:
Barkan, G.A., et al., The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. Acta Cytol, 2016.

6. Platform Technology Ideal for Bladder Cancer Surveillance
SynderBio
4/29/2019
Platform Technology Ideal for Bladder Cancer Surveillance
US 2014/ A1
PCT/US15/58255
Current instrument: small, benchtop device with disposable cartridge
Benign urothelial cells
Malignant cells
Benign cell debris
SynderBio
SynderBio Enhanced Cytology
Patented Approach
Enhanced Cytology
Eliminates benign cells, removes uncertainty, enables urine-based detection
Non-invasive Surveillance
Reduces frequency of invasive cystoscopy while preserving quality of patient care
Existing Workflow
Keeps both urologists and pathologists engaged
Low Cost
$15k instrument avoids capital purchase; Main revenue: $100 test kit
Contact:

7. SynderBio Enhanced Cytology Competitive Analysis
4/29/2019
SynderBio Enhanced Cytology Competitive Analysis
Company
Sensitivity
Specificity
Non-Invasive
Cost
SynderBio
Enhanced Cytology
High
Yes
$100
Traditional Urine-Based
Cytology
Low
$70
Cystoscopy No
$350
UroVysion™
(Abbott)
Yes*
$575
(Procedure Code: 88120)
NPM22
Bladderchek®
(Alere)
$50
*Must be used with cystoscopy
Contact:

8. Three Products Launched by 2021
SynderBio
4/29/2019
Three Products Launched by 2021
Research Labs – Direct Path to Market
Product 1:
Research Instrument
Requires FDA 510(k) Clearance to Market
Product 2:
Diagnostic Instrument I
Requires FDA 510(k) Clearance to Market
Product 3:
Diagnostic Instrument II
R&D Labs
Urology
Oncology
SBIR Awarded July 2017
STTR Awarded Sept 2017
Launch 2019
Launch 2020
Launch 2021
Contact:

9. Product-Market Fit in Major Markets
SynderBio
4/29/2019
Product-Market Fit in Major Markets
R&D Labs
Urology
Oncology
Non-invasive
Preserves Cell Quality
Fast, Accurate Diagnosis
$3.3B (Global )
Cell Separation (Cancer)
$1B (US )
Bladder Cancer Surveillance
$27B (Global )
Lab Testing (Cancer)
Launch 2019
Launch 2020
Launch 2021
Contact:

10. Need Validated through Customer Discovery
SynderBio
4/29/2019
Need Validated through Customer Discovery
R&D Labs
Urology
Oncology
Non-invasive
Preserves Cell Quality
Fast, Accurate Diagnosis
Contact:

11. Projected Financials for 2018-2022
SynderBio Corridor Angels Presentation
4/29/2019
Projected Financials for
Revenue Forecast
2018
2019
2020
2021
2022
Instrument Sales $
$ ,000
$ 2,390,000
$ 10,920,000
$ 28,410,000
Cartridge Sales
$ ,500
$ ,500
$ 10,123,000
$ 61,202,500
Non-equity funding
$ ,000
$ 1,000,000
$ ,000 $ $
Total revenue (w/grants)
$ 1,503,500
$ 3,312,500
$ 21,043,000
$ 89,612,500
Gross profit
$ 1,402,800
$ 2,745,280
$ 17,624,160
$ 76,651,120
Headcount 6 16 24 34 45
R&D/Eng/Outsource
$ ,848
$ 1,169,183
$ 2,362,527
$ 2,677,066
$ 3,190,827
Sales & Marketing
$ ,360
$ ,450
$ 1,029,135
$ 1,650,485
$ 2,315,618
G & A
$ ,836
$ ,563
$ ,798
$ ,572
$ 1,053,955
Total Expenses
$ 1,063,044
$ 2,250,196
$ 4,105,459
$ 5,249,123
$ 6,560,400
EBITDA
$ (438,044)
$ (847,396)
$ (1,360,179)
$ 12,375,037
$ 70,090,720
Product Launched
Contact:

12. We’re raising $1.5M with three goals over 18 months
SynderBio
4/29/2019
We’re raising $1.5M with three goals over 18 months
1. Support & expand key personnel
CEO, lead scientist
Engineering, Regulatory
2. Finalize first commercial product
Fabricate 10 pre-manufacture prototypes
Cultivate demand through beta tests with strategic customers
Launch in Q – Single Cell user base
3. Establish second product
First diagnostic product launch in 2020
Prepare for FDA 510(k) Pathway – begin clinical tests
Initial sales to large partners – to minimize S&M
Contact:

13. SynderBio
4/29/2019
Why SynderBio? Why Now?
Enabling technology for new products in rapidly growing fields
Single Cell Genomics
Non-invasive cancer surveillance
Cancer diagnostics based on Next Generation Sequencing
Personalized Medicine
Company is ready to go
Third party validation
IP issued, license obtained
Partner Interest
Fast path to revenue
Leveraging large non-dilutive investment
$175k in university/state funds directly to prototype/company development
$1.1M in federal funds to founder research
$525k in recent SBIR/STTR grants to company, opportunity to seek >$3M in Phase II
Two years of founder effort in company achievements
Contact:

14. Dedicated Leadership Team
SynderBio
4/29/2019
Dedicated Leadership Team
Mike Cable, PhD
Co-Founder, COO SynderBio Inc.
20 years experience with device-related startups-CEO, CTO, VP
Built first SynderBio working prototype
Michael Henry, PhD
Co-Founder, SynderBio Inc.
Deputy Director for Research, Holden Comprehensive Cancer Center
Cancer Biologist, made initial discoveries leading to SynderBio core technology
Formerly Senior Scientist, Millennium Pharmaceuticals
Christine Horton, BS
Board Chair, SynderBio Inc.
>20 years experience in executive leadership in medical device industry
Experience in key corporate areas including marketing, sales, regulatory
Sarah Vigmostad, PhD
Co-Founder, CTO SynderBio Inc.
Associate Professor, Biomedical Engineering, University of Iowa
Expertise in fluid mechanics, medical device design
Designed SynderBio prototype
Contact: or

15. SynderBio Corridor Angels Presentation
4/29/2019
SynderBio
Enabling Rapid and Accurate Cancer Diagnosis
THANK YOU
Contact:
© 2018 SynderBio, Inc.
Contact: